Gangrene Treatment Market Outlook:
Gangrene Treatment Market size was valued at USD 2.65 billion in 2024 and is projected to reach USD 5.36 billion by the end of 2037, rising at a CAGR of 6.9% during the forecast period, 2025-2037. In 2025, the industry size of gangrene treatment is evaluated at USD 2.84 billion.
The global gangrene treatment market is expanding due to the rise in the patient pool, reporting with an increase in the prevalence of diabetes mellitus, peripheral artery disease, and traumatic injuries. Based on the Centers for Disease Control and Prevention report in 2022, nearly 11.9% of the U.S. adult population has diabetes, which is approximately 37.6 million people, and diabetes is one of the leading causes of gangrene. Also, based on the National Institutes of Health report, nearly 8.6 million people in the U.S. above age 40 are affected by peripheral artery disease, and this often leads to ischemic tissue necrosis. The demand for treatment devices and instruments has increased due to budget allocation for gangrene treatment.
On the other hand, the gangrene-related therapeutics and devices production totally relies on the global chain of APIs, wound dressing, surgical tools, and hyperbaric systems. According to the U.S. International Trade Commission report, the U.S has imported surgical instruments and wound care devices, amounting to 3.7 billion in 2023. Government funding is also raised to support new trends and innovation in gangrene treatment, tissue preservation, and infection control technologies.
Gangrene Treatment Market - Growth Drivers and Challenges
Growth Drivers 
- Rising government healthcare expenditure: Medicare allocated nearly USD 862 million for gangrene-related treatment in the U.S in 2023. This allocation reflects the rising demand due to diabetes prevalence and the elderly population in the country. These conditions raise the risk of tissue necrosis and limb amputation. CMS has raised its medical coverage for wound debridement and hyperbaric oxygen therapy to improve hospital reimbursements and access to care. With chronic diseases increasing, governments are scaling federal spending to support limb preservation protocols, reducing costs associated with late-stage surgical interventions.
- Increasing patient pool with chronic diseases: In 2024, nearly 29.7 million diabetic foot ulcer cases were reported; if left untreated, there is an occurrence of a huge percentage advancing to gangrene. In Germany, above 2.2 million people are developing gangrenous complications and are at huge risk due to peripheral arterial disease and diabetes. This growing patient pool continues to drive the market for the requirement of early diagnosis, advanced surgical treatments, and wound management products. As chronic illness rates climb across both developed and emerging economies, demand for gangrene treatment solutions is expected to grow.
Historical Patient Growth & Its Impact on Market Dynamics
The prevalence of gangrene-related conditions globally has increased steadily from 2010 to 2020, with the rise in number of prevalence of diabetes and peripheral artery disease in the elderly population in various regions across the globe. Over the past ten years, there has been a massive increase in patient growth, which has led to the demand for gangrene treatment solutions, mainly in advanced hyperbaric oxygen therapy, wound care, surgical debridement, and targeted antibiotic formulations. The developed nations have early adoption of diagnostic infrastructure and chronic disease management programs, whereas emerging nations delay it due to the increase in public health spending and expanded rural outreach.
Historical Patient Growth (2010-2020) in Key Markets
|
Country |
2010 Patients (Millions) |
2020 Patients (Millions) |
Growth (%) |
|---|---|---|---|
|
USA |
2.5 |
3.5 |
62.0% |
|
Germany |
1.6 |
1.7 |
67.7% |
|
France |
1.2 |
1.6 |
59.9% |
|
Spain |
0.9 |
1.1 |
86.2% |
|
Australia |
0.7 |
0.9 |
81.7% |
|
Japan |
1.9 |
1.8 |
60.5% |
|
India |
1.5 |
2.9 |
102.9% |
|
China |
3.1 |
5.6 |
96.6% |
Strategic Expansion Models for Gangrene Treatment Market
The global gangrene treatment market has significantly elevated revenue generation. The feasibility models focus on localized manufacturing, healthcare integration and partnerships. The region-specific strategies implemented by key players in this sector collectively constructed a roadmap for new entrants. These models not only enable cost-effective treatment delivery but also align with government policies promoting affordable healthcare. Moreover, the value-based approach, such as technology upgradation, public-private partnerships (PPPs), and localized production, to business expansion is fostering a potential to garner new avenues in this category.
Feasibility Models for Revenue Growth
|
Country |
Expansion Model |
Revenue Growth (%) |
Key Approach |
|---|---|---|---|
|
India |
Public-private hospital partnerships |
+12.6% |
Leveraged district hospitals to scale low-cost wound care |
|
USA |
Medicare reimbursement expansion |
+10.9% |
Early-stage gangrene therapy coverage under CMS |
|
China |
National hospital procurement programs |
+18.8% |
Tiered pricing linked to hospital volume procurement |
|
Germany |
Integrated public-private vascular care model |
+9.6% |
Standardized early screening in outpatient settings |
|
Japan |
AMED-funded hospital innovation clusters |
+11.9% |
Regional collaboration on regenerative wound therapy |
|
Canada |
Telehealth expansion for rural wound care |
+8.0% |
Virtual triage and home-based debridement solutions |
|
France |
Public insurance alignment with biologics suppliers |
+8.6% |
Accelerated biologic dressing reimbursements via HAS |
|
South Korea |
Smart clinic integration with digital wound imaging |
+10.4% |
AI-driven gangrene diagnostics integrated into clinics |
Challenge
- Pricing restrictions and caps in government healthcare: Several countries have robust price caps on the advanced treatments for gangrene. This high cost is within their government-funded healthcare systems. For instance, in 2023, a company collaborated with a health authority in Germany to overcome these challenges in pricing, hence boosting the market access by 10.2%. Apart from these, reimbursement challenges often restrict the use of high-cost advanced biologic dressings by 20.2% among hospital patients.
Gangrene Treatment Market Size and Forecast:
| Report Attribute | Details |
|---|---|
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
6.9% |
|
Base Year Market Size (2024) |
USD 2.65 billion |
|
Forecast Year Market Size (2037) |
USD 5.36 billion |
|
Regional Scope |
|
Gangrene Treatment Market Segmentation:
End user Segment Analysis
Under the end user segmentation, hospitals and surgical centers are expected to dominate the gangrene treatment market with 38.8% in 2037. As hospitals and surgical centers are the crucial treatment hub for patients with gangrene, funded hospitals across various regions are maximizing the wound care departments for the elderly and diabetic population. Based on the report of the U.S. HHS, the reimbursement in Medicare has a broad space for surgical and post-operative wound management services to boost patient inflow. The World Health Organization's global health plan stresses infection control infrastructure development in hospital settings, which reinforces this tendency.
Treatment Segment Analysis
Surgical debridement is expected to dominate the treatment segment in the gangrene treatment market with 34.6% in 2037 due to its crucial role in gangrene’s life-threatening forms, mainly in wet and gas gangrene. Based on the NIH report, the aggressive surgical intervention remains the gold standard for early excision of necrotic tissue to prevent systemic infection and sepsis. The outcomes and accessibility in the advancements of minimally invasive surgical tools and the proliferation of wound care clinics have been improved. Further, the CDC recommends surgery as the first-line treatment for individuals with diabetes advanced limb-threatening infections.
Our in-depth analysis of the global gangrene treatment market includes the following segments: 
|
Segment |
Subsegment |
|
Treatment Type |
|
|
End user |
|
|
Distribution Channel |
|
Vishnu Nair
Head - Global Business DevelopmentCustomize this report to your requirements — connect with our consultant for personalized insights and options.
Gangrene Treatment Market - Regional Analysis
North America Market Insights
North America is expected to be the dominating region in the gangrene treatment market with 33.9% market share in 2037 and CAGR of 7.0%. The market in North America expands due to the increase in diabetics presence among the patients, also impacts on the medical coverage and advancements in the surgical and wound care technologies. Based on the report from Centers for Disease Control and Prevention above 150,010 U.S. hospitalizations YoY are linked with complications related to gangrene. Federal spending on infection treatment and wound are increased by 9.2% from 2021 to 2024 by reaching USD 5.4 billion as per AHRQ.
The gangrene treatment market in the U.S. is growing due to the aging and diabetic population with the increase in occurrence of ischemic and wet gangrene. Based on the CDC report above 11.3% of adults live with diabetes having high portion gangrene cases. The federal initiatives in the U.S. are actively investing in wound care infrastructure. Also, the NIH has allocated above USD 951 million in 2023 for infectious and vascular disease research which is the portion supports gangrene treatment innovations. The device adoption is high, with hospitals rapidly integrating advanced wound dressing systems and surgical kits.
Europe Market Insights
Europe is the fastest-growing region in the gangrene treatment market, expecting to have a market share of 28.5% in 2037. Nearly 20.2% of the elderly population in Europe is affected by peripheral arterial disease, which is reported by health.ec.europa.eu. Countries in Europe have lined up primary intervention strategies, including limb preservation programs and multidisciplinary wound care teams. The EU is actively increasing its investments in hospital infrastructure and hyperbaric oxygen therapy systems. Reimbursement harmonization across member states is also increasing treatment accessibility.
The gangrene treatment market in Germany has reached €4.2 billion in 2024, with a CAGR of 12.2% since 2021. The Federal Ministry of Health in Germany has implemented protocols like national wound management in collaboration with the German Medical Association to make faster patient pathways. Germany’s aging population and high diabetes incidence are raising the market and increasing demand. The Gesetzliche Krankenversicherung’s reimbursement framework covers pharmaceutical and surgical therapies with immunomodulators and enzyme-based debridement agents. Germany also leads the market with the adoption of digitized tracking and AI-assisted diagnostics.
Key Gangrene Treatment Market Players:
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
The market is highly consolidated with few multinational firms, holding dominant share via vertically integrated with advanced R&D ad supply chain pipelines. Additionally, the strategic PPPs and new launches are expanding the reach of this sector worldwide, even across underserved regions. Companies like Smith+Nephew, 3M, and Coloplast lead through innovation in wound care and infection control products. The efforts to make associated products more affordable through cost-optimized manufacturing and resource localizing are also propelling growth in this merchandise and attracting other developers, related to mental health, to invest in this category.
The top 20 cohort of such key players include:
|
Company Name (Country) |
Industry Focus (Within Gangrene Treatment Market) |
Estimated Market Share (2037) |
|---|---|---|
|
Smith+Nephew (UK) |
Advanced wound care, negative pressure wound therapy, debridement kits |
9.7% |
|
3M Health Care (USA) |
Wound dressings, antiseptics, surgical adhesives, and infection control |
9.0% |
|
Coloplast A/S (Denmark) |
Moist wound healing products, hydrocolloids, and foam dressings |
7.9% |
|
ConvaTec Group Plc (UK) |
Chronic wound treatment solutions, skin barrier products |
7.1% |
|
Molnlycke Health Care AB (Sweden) |
Foam dressings, surgical solutions, and infection prevention |
6.9% |
|
KCI Medical (USA) |
Negative pressure wound therapy systems (e.g., V.A.C. Therapy) |
xx% |
|
Medtronic Plc (Ireland/USA) |
Peripheral vascular interventions, revascularization devices |
xx% |
|
Organogenesis Holdings Inc. (USA) |
Bioactive wound care solutions, skin substitutes |
xx% |
|
Smiths Medical (USA) |
Hyperbaric oxygen systems, intravenous solutions |
xx% |
|
Integra LifeSciences (USA) |
Regenerative wound matrices, tissue-engineered dermal substitutes |
xx% |
|
Baxter International Inc. (USA) |
IV antibiotics, critical care solutions for infections |
xx% |
|
Hollister Incorporated (USA) |
Antimicrobial wound dressings, ostomy wound management |
xx% |
|
Nipro Corporation (Japan) |
Peripheral intervention tools, infection management |
xx% |
|
Toho Pharmaceutical (Japan) |
Antibiotics, surgical tools for vascular necrosis |
xx% |
|
Terumo Corporation (Japan) |
Advanced vascular access and wound closure systems |
xx% |
|
Wockhardt Ltd. (India) |
Broad-spectrum injectable antibiotics for sepsis & gangrene |
xx% |
|
Sun Pharmaceutical Industries Ltd. (India) |
Generic antibiotics and topical antibacterial treatments |
xx% |
|
CGBio (South Korea) |
Regenerative biomaterials, wound matrices, stem-cell wound solutions |
xx% |
|
Compumedics Ltd. (Australia) |
Hyperbaric therapy devices & infection monitoring systems |
xx% |
|
Duopharma Biotech Bhd (Malaysia) |
Localized infection treatments, antibacterial ointments |
xx% |
Below are the areas covered for each company in the gangrene treatment market:
Recent Developments
- In February 2024, 3M Health Care introduced 3M Tegaderm, a next-generation dressing, to enhance the ability of chronic wounds to retain moisture and act as an infection barrier. The product has reported an 8.5% YoY revenue increase, driven largely by adoption in U.S. Veterans Affairs hospitals.
- In June 2024, Organogenesis Holdings Inc. introduced PuraPly MZ, a product intended for wounds resistant to surgical debridement. This launch led 12.2% rise in advanced wound care sales in Q3 2024.
- Report ID: 3076
- Published Date: Jun 25, 2025
- Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
Gangrene Treatment Drugs Market Report Scope
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Connect with our Expert
